The Association of G9a Protein and the Outcome of Patients With Cervical Cancer

September 4, 2016 updated by: Sheng-Mou Hsiao, Far Eastern Memorial Hospital
G9a protein was approved to be highly associated with recurrence of breast cancer, gastric cancer, hepatocellular cancer, prostate cancer and lung cancer. Therefore, the aim of this study was to clarify the association and G9a protein and cervical cancer by analyzing the immunohistochemical staining of G9a protein to the histopathologic specimen of cervical cancer and clinical data.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

69

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
    • New Taipei
      • Banqiao, New Taipei, Taiwan, 22050
        • Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Patients with cervical cancer, and underwent primary treatment (surgery, radiotherapy or chemotherapy) in Far Eastern Memorial Hospital

Description

Inclusion Criteria:

  • cases with cervical cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
cervical cancer

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
determine whether G9a protein is a risk factor of overall survival of patients with cervical cancer
Time Frame: From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months
From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months

Secondary Outcome Measures

Outcome Measure
Time Frame
determine whether G9a protein is a risk factor of progression-free survival of patients with cervical cancer
Time Frame: From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months
From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Far Eastern Memorial Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2012

Primary Completion (Actual)

February 1, 2015

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

December 27, 2011

First Submitted That Met QC Criteria

January 6, 2012

First Posted (Estimate)

January 9, 2012

Study Record Updates

Last Update Posted (Estimate)

September 7, 2016

Last Update Submitted That Met QC Criteria

September 4, 2016

Last Verified

July 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 100078-E

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe